Investigating the Genetic Effect of HLA on the Response to Immunotherapy in Patients with Classic Hodgkin Lymphoma

The genetic makeup of individuals, especially the human leukocyte antigen (HLA) alleles, significantly influences the functionality of the immune system and its interaction with various therapeutic approaches. Classic Hodgkin Lymphoma (cHL) is a specific type of lymphatic cancer where immunotherapy has emerged as a pivotal treatment option. This study aims to investigate the genetic impact of HLA on the effectiveness of immunotherapy among patients diagnosed with cHL, focusing on identifying specific HLA alleles that are associated with either improved or diminished therapeutic outcomes. Materials and Methods: The study involved a cohort of ۱۲۰ patients diagnosed with classic Hodgkin Lymphoma, consisting of ۷۰ males and ۵۰ females, with an average age of ۳۴ years, spanning from ۱۸ to ۶۵ years. HLA typing was conducted utilizing high-resolution molecular techniques to ensure accurate identification of alleles. Throughout the study, patients were closely monitored over a ۱۲-month period to assess their responses to immunotherapy. The primary outcome measures included the expression levels of critical immunological markers and the clinical response rates of the patients. Results: Among the ۱۲۰ patients evaluated, ۴۵ individuals demonstrated a complete response to immunotherapy, with HLA-DRB۱۱۵ present in ۲۰ of these responders. A partial response was recorded in ۳۵ patients, where HLA-A۰۲ was identified in ۱۵ cases. Conversely, ۴۰ patients showed no significant response to treatment, with HLA-B*۰۸ detected in ۱۸ of the non-responders. The analysis of the data revealed a significant correlation between specific HLA alleles and patient response rates to immunotherapy, underscoring the potential role of genetic factors in treatment efficacy. Conclusion: The findings from this study indicate that certain HLA alleles, specifically HLA-DRB۱۱۵ and HLA-A۰۲, are linked to a more favorable response to immunotherapy in patients suffering from classic Hodgkin Lymphoma. In contrast, the presence of HLA-B*۰۸ appears to be associated with a reduced response rate to treatment. These results emphasize the critical role of genetic profiling in predicting patient outcomes and suggest that such information could be instrumental in guiding personalized therapeutic strategies for individuals diagnosed with cHL.

کلیدواژه ها:

Classic Hodgkin Lymphoma ، HLA ، Immunotherapy ، Treatment Response ، Personalized Medicine